Cargando…

Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina

Background: Quadrivalent cell-based influenza vaccines (QIVc) avoid egg-adaptive mutations and can be more effective than traditional quadrivalent egg-based influenza vaccines (QIVe). This analysis compared the cost-effectiveness of QIVc and QIVe in Argentinian populations < 65 years old from the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Urueña, Analía, Micone, Paula, Magneres, María Cecilia, McGovern, Ian, Mould-Quevedo, Joaquin, Sarmento, Túlio Tadeu Rocha, Giglio, Norberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612026/ https://www.ncbi.nlm.nih.gov/pubmed/36298493 http://dx.doi.org/10.3390/vaccines10101627

Ejemplares similares

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
por: Urueña, Analia, et al.
Publicado: (2021)

1435. The Cost-Effectiveness of Vaccinating With an Adjuvanted Trivalent Influenza Vaccine for the 65+ Population in Argentina
por: Nguyen, Van, et al.
Publicado: (2018)

Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
por: Giorgi, Mariano Anibal, et al.
Publicado: (2015)

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion
por: Postma, Maarten, et al.
Publicado: (2023)

1166. The Cost-Effectiveness Evidence of Enhanced Influenza Vaccines in Adults ≥65 Years of Age: A Literature Review and Decision-Making Implications
por: Giglio, David FismanNorberto, et al.
Publicado: (2023)

Public health and economic benefits of new pediatric influenza vaccination programs in Argentina
por: Giglio, Norberto, et al.
Publicado: (2012)

Meningococcal burden of disease in Argentina: 10 years epidemiologic review
por: Neyro, Silvina, et al.
Publicado: (2023)

Cost-Effectiveness of the Use of Adjuvanted Quadrivalent Seasonal Influenza Vaccine in Older Adults in Ireland
por: Nguyen, Van Hung, et al.
Publicado: (2023)

Epidemiological study of influenza virus infections in young adult outpatients from Buenos Aires, Argentina
por: Santamaría, Cecilia, et al.
Publicado: (2008)

Estimating the Impact of Influenza Vaccination on Acute and ICU Hospital Bed Usage in an Influenza Season under Endemic COVID-19 in the US
por: Nguyen, Van Hung, et al.
Publicado: (2022)

Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States
por: Krishnarajah, Girishanthy, et al.
Publicado: (2021)

25. Relative Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-Based Trivalent High-Dose Influenza Vaccine among U.S. Older Adults during 2019-20 Influenza Season
por: levin, myron J, et al.
Publicado: (2021)

Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season
por: Pelton, Stephen I., et al.
Publicado: (2020)

A Real-World Clinical and Economic Analysis of Cell-Derived Quadrivalent Influenza Vaccine Compared to Standard Egg-Derived Quadrivalent Influenza Vaccines During the 2019–2020 Influenza Season in the United States
por: Divino, Victoria, et al.
Publicado: (2021)

Estimating the impact of influenza vaccination of low-risk 50–64-year-olds on acute and ICU hospital bed usage in an influenza season under endemic COVID-19 in the UK
por: Nguyen, Van Hung, et al.
Publicado: (2023)

Trends in Varicella Burden of Disease Following Introduction of Routine Childhood Varicella Vaccination in Argentina: A 12-Year Time Series Analysis
por: Giglio, Norberto, et al.
Publicado: (2022)

REAL-WORLD EFFECTIVENESS ENHANCED INFLUENZA VACCINES IN OLDER ADULTS DURING THREE CONSECUTIVE INFLUENZA SEASONS: 2017–2020
por: McGovern, Ian
Publicado: (2022)

6. MF59 ASSURANCE 2: A Real-world Study to Estimate the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-based Trivalent High-dose Among U.S. Older Adults During 2018–19 Influenza Season
por: Pelton, Stephen I, et al.
Publicado: (2020)

29. Impact of Enhanced Influenza Vaccines on Direct Healthcare Costs for the U.S. Elderly: A Comprehensive Real-World Evaluation of Adjuvanted Trivalent Influenza Vaccine Compared to Trivalent High-Dose Influenza Vaccine for the 2018–19 Influenza Season
por: Postma, Maarten, et al.
Publicado: (2020)

2640. Estimated Additional Burden Averted from Use of Cell-Based Influenza Vaccines Compared to Egg-Based Influenza Vaccines Among People 0-64 Years of Age in the United States: 2017-2020 Seasons
por: McGovern, Ian, et al.
Publicado: (2023)

14. A Comprehensive Real-World Analysis to Compare Adjuvanted Trivalent Influenza Vaccine and Trivalent High Dose Influenza Vaccine by Age and Period of High Influenza Activity for the 2018–19 Season among U.S. Elderly
por: Postma, Maarten, et al.
Publicado: (2020)

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

1732. The Value of the Influenza Cell-Based Vaccine in the Pediatric Population. A Dynamic Transmission Modelling Approach in the U.S.
por: Mould-Quevedo, Joaquin F, et al.
Publicado: (2023)

902. Incidence of Influenza-Related Medical Encounters Among Adults in The United States During the 2015-2020 Influenza Seasons
por: McGovern, Ian, et al.
Publicado: (2023)

Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina
por: Rombini, Fernanda, et al.
Publicado: (2020)

Additional Burden Averted in the United States From Use of MF59-Adjuvanted Seasonal Influenza Vaccine Compared With Standard Seasonal Influenza Vaccine Among Adults ≥65 Years
por: McGovern, Ian, et al.
Publicado: (2023)

Effectiveness of Cell-Based Quadrivalent Seasonal Influenza Vaccine: A Systematic Review and Meta-Analysis
por: Coleman, Brenda L., et al.
Publicado: (2023)

The Epidemiological and Economic Impact of a Cell-Based Quadrivalent Influenza Vaccine in Adults in the US: A Dynamic Modeling Approach
por: Nguyen, Van Hung, et al.
Publicado: (2021)

Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis
por: Levin, Myron J., et al.
Publicado: (2021)

Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States
por: Boikos, Constantina, et al.
Publicado: (2022)

The Impact of Adjuvanted Influenza Vaccine on Disease Severity in the US: A Stochastic Model
por: Pelton, Stephen I., et al.
Publicado: (2023)

Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Children: A Narrative Review
por: Mould-Quevedo, Joaquin F., et al.
Publicado: (2023)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

1167. The Value of Influenza Vaccination in the Older Adult Population. A Stochastic Model Estimation of the benefit of vaccination to prevent the Severe Outcomes in the U.S.
por: Pelton, Stephen I, et al.
Publicado: (2023)

Review of Analyses Estimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive US Influenza Seasons
por: Boikos, Constantina, et al.
Publicado: (2022)

Single-Dose Universal Hepatitis A Immunization in 1-Year-Old Infants in Argentina: High Prevalence of Protective Antibodies up to 11 Years Following Vaccination
por: Urueña, Analia, et al.
Publicado: (2017)

Global patterns of seasonal influenza activity, duration of activity and virus (sub)type circulation from 2010 to 2020
por: Zanobini, Patrizio, et al.
Publicado: (2022)

The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

Low selection rate of HLA-anchor escape mutations in HIV after transmission of subtype B and recombinants BF strains patients from Argentina
por: Damilano, G, et al.
Publicado: (2012)

Epidemiology and Burden of Influenza in Children 0–14 Years Over Ten Consecutive Seasons in Italy
por: Barbieri, Elisa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o059th8b3qc5pkfubjiksa9st0